Compare Noble Corporation plc (NE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs TG Therapeutics Inc — how do they compare? Noble Corporation plc trades at $42.36 (market cap $6.73B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Noble Corporation plc pays a 4.74% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and TG Therapeutics Inc for 16 Days on average.
| NE | TGTX | |
|---|---|---|
Market Cap | $6.73B | $8.16B |
Volume | 1,027,635 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $54.37 | $59.06 |
52-Week Low | $26.70 | $26.94 |
Typical Hold Time | 26 Days | 16 Days |
Enterprise Value | $8.16B | $8.37B |
Dividend Yield | 4.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $42.15, up 2.88% today, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported $3.29B revenue for 2025 with 6.59% net margin, though 2026 projections show declining revenue and profitability. Recent news includes a long-term drilling contract with Tullow in Ghana, providing operational visibility into 2027.
The stock faces headwinds from declining earnings momentum and ongoing legal investigations, offset by positive analyst sentiment with a $52 consensus target representing 23% upside. Key risks include execution challenges in a volatile energy market and potential legal liabilities from the Pomerantz investigation announced September 2026.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
